



Article

New 2-[(4-Amino-6-*N*-substituted-1,3,5-triazin-2-yl)methylthio]-*N*-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide Derivatives, Design, Synthesis and Anticancer Evaluation

Łukasz Tomorowicz ¹, Beata Żołnowska ¹, Krzysztof Szafranski ¹, Jarosław Chojnacki ², Ryszard Konopiński ³, Ewa A. Grzybowska ³, Jarosław Sławiński ^{1,*} and Anna Kawiak ^{4,*}

¹ Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland; ltomorowicz@gumed.edu.pl (Ł.T.); zolnowska@gumed.edu.pl (B.Ż.); k.szafranski@gumed.edu.pl (K.S.)

² Department of Inorganic Chemistry, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, 80-233 Gdańsk, Poland; jaroslaw.chojnacki@pg.edu.pl

³ Maria Skłodowska-Curie National Research Institute of Oncology, ul. Roentgena 5, 02-781 Warszawa, Poland; ryszard.konopinski@pib-nio.pl (R.K.); ewa.grzybowska@pib-nio.pl (E.A.G.)

⁴ Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, ul. Abrahama 58, 80-307 Gdańsk, Poland

* Correspondence: jaroslaw@gumed.edu.pl (J.S.); anna.kawiak@biotech.ug.edu.pl (A.K.); Tel.: +48-58-349-10-98 (J.S.); +48-58-523-63-08 (A.K.)



Citation: Tomorowicz, Ł.; Żołnowska, B.; Szafranski, K.; Chojnacki, J.; Konopiński, R.; Grzybowska, E.A.; Sławiński, J.; Kawiak, A. New 2-[(4-Amino-6-*N*-substituted-1,3,5-triazin-2-yl)methylthio]-*N*-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide Derivatives, Design, Synthesis and Anticancer Evaluation. *Int. J. Mol. Sci.* **2022**, *23*, 7178. <https://doi.org/10.3390/ijms23137178>

Academic Editors: Antonio Rescifina and Andrea Pace

Received: 20 May 2022

Accepted: 24 June 2022

Published: 28 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: In the search for new compounds with antitumor activity, new potential anticancer agents were designed as molecular hybrids containing the structures of a triazine ring and a sulfonamide fragment. Applying the synthesis in solution, a base of new sulfonamide derivatives **20–162** was obtained by the reaction of the corresponding esters **11–19** with appropriate biguanide hydrochlorides. The structures of the compounds were confirmed by spectroscopy (IR, NMR), mass spectrometry (HRMS or MALDI-TOF/TOF), elemental analysis (C,H,N) and X-ray crystallography. The cytotoxic activity of the obtained compounds toward three tumor cell lines, HCT-116, MCF-7 and HeLa, was examined. The results showed that some of the most active compounds belonged to the $R^1 = 4$ -trifluoromethylbenzyl and $R^1 = 3,5$ -bis(trifluoromethyl)benzyl series and exhibited IC_{50} values ranging from 3.6 μ M to 11.0 μ M. The SAR relationships were described, indicating the key role of the $R^2 = 4$ -phenylpiperazin-1-yl substituent for the cytotoxic activity against the HCT-116 and MCF-7 lines. The studies regarding the mechanism of action of the active compounds included the assessment of the inhibition of MDM2-p53 interactions, cell cycle analysis and apoptosis induction examination. The results indicated that the studied compounds did not inhibit MDM2-p53 interactions but induced G0/G1 and G2/M cell cycle arrest in a p53-independent manner. Furthermore, the active compounds induced apoptosis in cells harboring wild-type and mutant p53. The compound design was conducted step by step and assisted by QSAR models that correlated the activity of the compounds against the HCT-116 cell line with molecular descriptors.

Keywords: benzenesulfonamide; synthesis; 1,3,5-triazines; imidazole; QSAR; anticancer activity; cell cycle arrest; proliferation; apoptosis

1. Introduction

Cancers are the leading cause of death worldwide. The WHO reports that, in 2020, the number of deaths from cancer was almost 10 million. The most common cancers in terms of new cases in 2020 were: breast cancer (2.26 million cases), lung cancer (2.21 million cases), colon and rectal cancer (1.93 million cases), prostate cancer (1.41 million cases), skin cancer (non-melanoma) (1.20 million cases) and stomach cancer (1.09 million cases). The most common causes of cancer deaths in 2020 were lung cancer (1.80 million deaths), colon and rectal cancer (935,000 deaths), liver cancer (830,000 deaths), stomach cancer

(769,000 deaths), and breast cancer (685,000 deaths) [1]. The most common cancers are colorectal cancers, including colon and breast cancer. This fact has led us to focus our research, among others, on the cancer cell lines of breast cancer (MCF-7) and colon cancer (HCT-116).

Chemotherapy, radiotherapy and surgery are the most popular methods of cancer treatment available nowadays [2]. Multi-drug resistance (MDR) is one of the main problems of long-term chemotherapy failure [3,4]. For some types of cancer, e.g., pancreatic cancer, no effective chemotherapeutic agents have been found so far, and the only method of choice with a minimum survival of 5 years is surgical resection, which is less than 5% effective [5]. On the other hand, in the case of surgically inoperable cancers (which include the majority of infiltrating cancers and those located in places inaccessible for surgical treatment), chemotherapy [6,7], hormone therapy [7], immunotherapy [8] and radiotherapy [7] are the main treatment options.

Undoubtedly, compounds containing a sulfonamide moiety belong to a wide group of chemotherapeutic agents that have been used as anticancer agents. One good example can be Vemurafenib, which has been used since 2011 in the chemotherapy of melanomas with the BRAF V600 mutation [9]. Vemurafenib is currently in phase two clinical trials for colorectal cancer patients with the BRAF mutation in the VIC regimen [10] and for non-small cell lung cancer [11]. Another sulfonamide compound, E7010 (Figure 1), is presently in phase two clinical trials in colorectal cancer patients [12]. In turn, Enasidenib, approved by the FDA in 2017 [13], containing the 1,3,5-triazine moiety, is used in relapsed or refractory acute myeloid leukemia (AML), and Gedatolisib (Figure 1) is used in combination either with Talazoparib, at present in phase two clinical trials for breast cancer [14], or Palbociclib, in phase one clinical trials for patients with head and neck, pancreatic, lung and solid tumors [15].




Figure 1. Structures of exemplary anticancer drugs and compounds containing a sulfonamide or 1,3,5-triazine moiety which are in clinical trials, among others, for breast or colorectal cancer.

Our previous reports indicated that 4-chloro-2-arylmethylthio-5-methylbenzenesulfonamide derivatives show cytotoxic activity against numerous human cancer cell lines, including colon, breast and cervical cancer, among others [16–19]. We have also proved that some of these compounds showed an apoptotic effect in cancer cells. In this work, we developed a series of 2-[(4-amino-6- R^2 -1,3,5-triazin-2-yl)methylthio]-*N*-(1- R^1 -imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamides (Figure 2), applying the molecular hybrids strategy. Molecular hybrids were designed as a combination of 2-mercaptobenzenesulfonamide fragments (A) with a 4-amino-6- R^2 -1,3,5-triazin-2-yl ring (B). The structures of the designed compounds were also diversified with the substituent R^1 (C) (Figure 2) on the imidazolidine ring in position *N*-1 to investigate their influence on cytotoxic activity.




Figure 2. The general structure of a designed molecular hybrid consisting of two pharmacophores: a 2-mercaptobenzenesulfonamide fragment (A) and a 4-amino-6- R^2 -1,3,5-triazin-2-yl ring (B), modified by the R^1 substituent (C) on the *N*-1 imidazolidine ring.

The quantitative structure–activity relationship (QSAR) computational method is helpful in the design and development of new anticancer active compounds [20–22]. Thus, a series of 2-[(4-amino-6- R^2 -1,3,5-triazin-2-yl)methylthio]-*N*-(1- R^1 -imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide derivatives (20–157) were synthesized in four separate steps, which required the building of QSAR models and introducing structural modifications, leading to better cytotoxic activities (Figure 3). All synthesized compounds were tested in a series designed sequentially for their cytotoxic activity against three human cancer cell lines, i.e., HCT-116, MCF-7, and HeLa. The resulting experimental data for the HCT-116 cell lines were consequently used for QSAR analysis. QSAR models were constructed step by step for a series of structurally modified compounds with $R^1 = \text{H}$ (Step 1), Bn (Step 2), and 4-F-Bn (Step 3). The predictive performance of the models built for the compounds from Step 3 allowed for the virtual design of a subsequent series modified in the *N*-1 position of imidazolidine ring with $R^1 = 3\text{-F}_3\text{C-Bn}$, 4- $\text{F}_3\text{C-Bn}$, and 3,5-bis(F_3C)Bn (Step 4).





Figure 3. A pathway of the designing of 2-[(4-amino-6- R^2 -1,3,5-triazin-2-yl)methylthio]-*N*-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide derivatives based on QSAR models.

2. Results and Discussion

2.1. Chemistry

The necessary substrates, i.e., 4-chloro-2-mercapto-5-methyl-*N*-(1- R^1 -benzylimidazolidin-2-ylidene)benzenesulfonamide (2, 3), were synthesized by the methods previously described [23,24]. The novel substrates 4–9 and 10 were obtained analogously to the reaction of 1 with either ethane-1,2-diamine, *N*-benzylethane-1,2-diamine (4–9) or *N*-(4-trifluoromethylbenzyl)propane-1,3-diamine (10). Subsequent reaction of 2–10 with ethyl bromoacetate and triethylamine (TEA) in methylene chloride (DCM), led to the appropriate novel ethyl 2-[2-[*N*-(imidazolidin-2-ylidene)sulfamoyl or *N*-(tetrahydropyrimidin-2(1*H*)-ylidene)sulfamoyl]-5-chloro-4-methylphenylthio]acetate derivatives 11–18 and 19, respectively (Scheme 1).



Scheme 1. Synthesis of ethyl 2-[2-[N-(1-R¹-imidazolidin-2-ylidene)sulfamoyl]-5-chloro-4-methylphenylthio]acetate **11–18** and ethyl 2-[2-[N-[1-[4-(trifluoromethyl)benzyl]tetrahydropyrimidin-2(1H)-ylidene]sulfamoyl]-5-chloro-4-methylphenylthio]acetate **19**. Reagents and conditions: (a) appropriate diamine (0.04 mol), anhydrous MeOH, reflux 70–240 h; (b) *N*-(4-trifluoromethylbenzyl)propane-1,3-diamine (0.04 mol), anhydrous MeOH, reflux 123 h; (c) ethyl 2-bromoacetate (0.024 mol), TEA (0.02 mol), DCM.

Aiming for the synthesis of the final 6-substituted 4-amino-1,3,5-triazin-2-yl derivatives **20–157** (Scheme 2) and **158–162** (Scheme 3), the esters **11–18** or **19** were reacted with the appropriate biguanide hydrochlorides [25–30] in MeONa/MeOH solution at reflux for 45 h.



The structures of the final compounds **20–162** were confirmed with the IR and NMR methods, as well as HRMS (ESI-TOF) or MALDI-TOF/TOF, elemental analysis (C,H,N) and X-ray crystallography of the representative compound **27**.

X-ray crystallography was undertaken to study the structure of the representative compound **27**. Compound **27** forms transparent crystals satisfying the symmetry of the triclinic system, space group $P\bar{1}$ (no. 2). An asymmetric unit contains one molecule, and the whole unit cell is built from two molecules of the sulfonamide and two (disordered) molecules of solvent, DMSO, $Z = 2$. Most of the bond lengths and angles are in the expected ranges. The obtained molecular structure is presented in Figures 4 and 5. The report and details on data collection, structure solution, refinement geometry parameters, and hydrogen bonding details for **27** are given in Supplementary Materials (Tables S1 and S2).


2.2. Cytotoxic Activity

Compounds **20–162** were evaluated in vitro for their effects on the viability of three cancer cell lines: HCT-116 (colon cancer), MCF-7 (breast cancer) and HeLa (cervical cancer), as well as the non-cancerous keratinocyte cell line (HaCaT). The concentration required for 50% inhibition of cell viability IC₅₀ was calculated and, as a positive control, cisplatin was used. Analysis was performed using an MTT assay after 72 h of incubation. The results are shown in Tables 1–5.

The most active compounds **135**, **143**, **150** and **156** belonged to the R¹ = 4-trifluoromethylbenzyl (**135**, **143**) and R¹ = 3,5-bis(trifluoromethyl)benzyl (**150**, **156**) series and showed high activity (3.6–5.0 μM, 4.5–7.5 μM and 5.5–11.0 μM, respectively) against all tested cell lines, HCT-116, MCF-7 and HeLa. The selectivity indexes of the most active compounds ranged from 6.4 to 1.7 (Table 6). In turn, twelve compounds, **20–23**, **30**, **67**, **69–71**, **79–80** and **118**, were inactive for all tested cell lines, which is about eight percent of the tested compounds (Tables 1–5).

NphCH₂ - (naphthalen-1-yl)methyl

Scheme 2. Synthesis of 2-[(4-amino-6-R²-1,3,5-triazin-2-yl)methylthio]-N-(1-R¹-imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamides (20–157). Compounds synthesized previously [31].



Scheme 3. Synthesis of 2-[(4-amino-6-R²-1,3,5-triazin-2-yl)methylthio]-N-(1-[4-(trifluoromethyl)benzyl]tetrahydropyrimidin-2(1H)-ylidene)-4-chloro-5-methylbenzenesulfonamides (158–162).




Figure 4. Molecular structure of compound 27, showing the atom-labelling scheme. Solvent molecules omitted. Displacement ellipsoids are shown at 50% probability.





Figure 5. Crystal packing and hydrogen bonding in 27. Molecules of the main component are linked by the ring-type hydrogen bond motif $R_2^2(8)$ $\text{NH} \cdots \text{N}$ (using N4 and N8 atoms) located at the inversion center (drawn as the orange ball). The two dimethylsulfoxide molecules are interacting with the sulfonamide through $\text{NH} \cdots \text{O}$, $\text{CH} \cdots \text{O}$ or $\text{NH} \cdots \text{S}$ hydrogen bonds.

Table 1. Cytotoxicity of *N*-(imidazolidin-2-ylidene)benzenesulfonamides **20–44** toward human cancer cell lines and non-cancerous line HaCaT. Cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa), and the human keratinocyte cell line (HaCaT).



Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
20		110.0 ± 2.0	220.0 ± 6.0	115.0 ± 7.0	NT
21		350.0 ± 7.0	190.0 ± 2.0	510.0 ± 5.0	NT
22		140.0 ± 3.0	130.0 ± 4.0	110.0 ± 4.0	NT
23		142.0 ± 4.0	130.0 ± 3.0	150.0 ± 2.0	NT
24		20.0 ± 0.4	27.0 ± 0.3	22.0 ± 0.2	41.0 ± 1.0
25		45.0 ± 2.0	46.0 ± 2.0	46.0 ± 2.0	54.0 ± 2.0
26		33.0 ± 2.0	33.0 ± 1.0	34.0 ± 1.0	45.0 ± 2.0
27		39.0 ± 2.0	44.0 ± 1.0	74.0 ± 2.0	75.0 ± 3.0
28		58.0 ± 0.6	45.0 ± 0.5	80.0 ± 1.0	NT
29		25.0 ± 0.5	24.0 ± 0.2	32.0 ± 0.3	43.0 ± 2.0
30		170.0 ± 3.0	145.0 ± 7.0	153.0 ± 5.0	NT
31		10.0 ± 0.4	16.0 ± 0.2	16.0 ± 0.1	26.0 ± 1.0
32		14.0 ± 0.5	16.0 ± 0.5	14.0 ± 0.5	28.0 ± 1.0
33		19.0 ± 0.5	26.0 ± 1.0	25.0 ± 1.0	41.0 ± 2.0
34		18.0 ± 1.0	12.0 ± 0.5	24.0 ± 2.0	41.0 ± 1.0
35		14.0 ± 0.7	16.0 ± 1.0	16.0 ± 1.0	32.0 ± 2.0
36		12.0 ± 0.1	13.0 ± 0.1	12.0 ± 0.1	28.0 ± 1.0
37		18.0 ± 0.5	19.0 ± 1.0	24.0 ± 1.0	37.0 ± 2.0
38		15.0 ± 0.5	28.0 ± 1.0	19.0 ± 1.0	35.0 ± 1.0
39		15.0 ± 1.0	17.0 ± 1.0	18.0 ± 1.0	37.0 ± 2.0
40		21.0 ± 0.5	28.0 ± 2.0	23.0 ± 1.0	45.0 ± 3.0
41		21.0 ± 1.0	46.0 ± 1.0	39.0 ± 2.0	51.0 ± 3.0
42		31.0 ± 1.0	31.0 ± 2.0	30.0 ± 1.5	61.0 ± 4.0
43		17.0 ± 1.0	22.0 ± 0.5	19.0 ± 0.5	43.0 ± 2.0
44		14.0 ± 0.5	16.0 ± 0.5	14.0 ± 0.5	28.0 ± 1.0
cisplatin		3.8 ± 0.1	3.0 ± 0.1	2.2 ± 0.1	7.7 ± 0.2

NT—not tested; IC₅₀ values are expressed as the mean ± SD of at least three independent experiments.

Table 2. Cytotoxicity of *N*-(1-benzylimidazolidin-2-ylidene)benzenesulfonamides **45–73** and *N*-(1-naphthylimidazolidin-2-ylidene)benzenesulfonamides **74–81** toward human cancer cell lines and non-cancerous line HaCaT. Cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa), and the human keratinocyte cell line (HaCaT).

Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
45		19.0 ± 0.4	22.0 ± 0.2	34.0 ± 1.0	43.0 ± 2.0
46		21.0 ± 0.2	23.0 ± 0.7	37.0 ± 0.4	NT
47		19.0 ± 0.2	20.0 ± 0.4	34.0 ± 0.3	45.0 ± 2.0
48		6.0 ± 0.1	7.0 ± 0.2	25.0 ± 0.3	33.0 ± 1.0
49		14.0 ± 0.1	17.0 ± 0.3	24.0 ± 0.5	38.0 ± 1.0
50		18.0 ± 0.2	43.0 ± 1.0	35.0 ± 2.0	51.0 ± 2.0
51		19.0 ± 0.6	10.0 ± 0.5	15.0 ± 1.0	220.0 ± 12.0
52		37.0 ± 0.5	64.0 ± 2.0	61.0 ± 2.0	92.0 ± 3.0
53		10.0 ± 0.5	11.0 ± 0.5	85.0 ± 2.0	81.0 ± 4.0
54		11.0 ± 0.1	12.0 ± 0.1	16.0 ± 0.2	28.0 ± 1.0
55		7.0 ± 0.1	10.0 ± 0.2	13.0 ± 0.1	39.0 ± 2.0
56		22.0 ± 1.0	54.0 ± 1.0	37.0 ± 1.0	58.0 ± 2.0

Table 2. Cont.



Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
57		8.0 ± 0.1	8.0 ± 0.2	102.0 ± 2.0	48.0 ± 2.0
58		11.0 ± 0.3	17.0 ± 1.0	14.0 ± 2.0	29.0 ± 1.0
59		13.0 ± 0.3	18.0 ± 1.0	15.0 ± 1.0	30.0 ± 1.0
60		8.0 ± 0.3	14.0 ± 0.3	9.0 ± 0.5	23.0 ± 1.0
61		6.5 ± 0.1	9.0 ± 0.3	10.0 ± 0.2	21.0 ± 1.0
62		6.0 ± 0.1	7.0 ± 0.1	107.0 ± 1.0	32.0 ± 1.0
63		7.0 ± 0.1	9.0 ± 0.5	12.0 ± 0.5	24.0 ± 1.0
64		11.0 ± 0.4	14.0 ± 0.5	15.0 ± 1.0	28.0 ± 1.0
65		7.0 ± 0.2	11.0 ± 0.5	11.0 ± 0.3	23.0 ± 1.0
66		12.0 ± 0.4	29.0 ± 1.0	20.0 ± 1.0	36.0 ± 2.0
67		168.0 ± 8.0	153.0 ± 5.0	140.0 ± 7.0	NT
68		16.0 ± 0.5	16.0 ± 0.5	14.0 ± 0.5	32.0 ± 2.0
69		66.0 ± 2.0	122.0 ± 7.0	100.0 ± 6.0	128.0 ± 5.0
70		300.0 ± 18.0	490.0 ± 10.0	550.0 ± 21.0	NT
71		155.0 ± 6.0	205.0 ± 4.0	265.0 ± 8.0	27.0 ± 1.0
72		6.5 ± 0.1	9.0 ± 0.5	17.0 ± 0.5	28.0 ± 1.0
73		5.2 ± 0.2	7.5 ± 0.3	14.0 ± 0.3	29.0 ± 1.0
74		44.0 ± 2.0	12.0 ± 0.6	13.0 ± 0.5	81.0 ± 4.0
75		30.0 ± 2.0	8.0 ± 0.5	77.0 ± 5.0	110.0 ± 5.0
76		46.0 ± 1.0	25.0 ± 1.0	28.0 ± 2.0	99.0 ± 4.0
77		40.0 ± 1.0	29.0 ± 1.0	110.0 ± 5.0	220.0 ± 11.0
78		19.5 ± 0.6	11.0 ± 0.5	130.0 ± 8.0	280.0 ± 14.0
79		94.0 ± 2.0	98.0 ± 5.0	88.0 ± 3.0	NT
80		79.0 ± 2.0	89.0 ± 4.0	98.0 ± 5.0	NT
81		8.4 ± 0.3	8.0 ± 0.5	63.0 ± 1.0	240.0 ± 12.0
cisplatin		3.8 ± 0.1	3.0 ± 0.1	2.2 ± 0.1	7.7 ± 0.2

NT—not tested; IC₅₀ values are expressed as the mean ± SD of at last three independent experiments.

Table 3. Cytotoxicity of *N*-[1-(4-fluoro or bromo)benzylimidazolidin-2-ylidene]benzenesulfonamides **82–111** toward human cancer cell lines and non-cancerous line HaCaT. Cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa), and the human keratinocyte cell line (HaCaT).

Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
82		19.0 ± 0.8	12.0 ± 0.1	30.0 ± 1.0	54.0 ± 2.0
83		10.0 ± 0.5	14.0 ± 1.0	12.0 ± 3.0	32.0 ± 1.0
84		9.0 ± 0.5	7.0 ± 0.1	15.0 ± 0.6	27.0 ± 1.0
85		15.0 ± 0.5	23.0 ± 1.0	21.0 ± 4.0	38.0 ± 1.0
86		13.0 ± 0.5	15.0 ± 0.2	16.0 ± 0.2	35.0 ± 2.0
87		10.0 ± 0.4	7.0 ± 0.3	15.0 ± 1.0	34.0 ± 1.0
88		17.0 ± 0.5	31.0 ± 1.0	25.0 ± 2.0	43.0 ± 2.0
89		14.0 ± 0.7	18.0 ± 1.0	17.0 ± 0.6	31.0 ± 1.0
90		12.0 ± 0.2	17.0 ± 1.0	15.0 ± 0.6	30.0 ± 2.0

Table 3. Cont.

Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
91		20.0 ± 1.0	13.0 ± 0.4	34.0 ± 2.0	54.0 ± 2.0
92		7.0 ± 0.3	8.0 ± 0.4	8.0 ± 0.5	18.0 ± 1.0
93		7.0 ± 0.3	7.0 ± 0.5	8.0 ± 0.4	18.0 ± 1.0
94		9.0 ± 0.2	14.0 ± 0.5	12.0 ± 1.0	25.0 ± 1.0
95		7.0 ± 0.3	7.0 ± 0.1	8.0 ± 0.4	18.0 ± 1.0
96		6.0 ± 0.3	6.0 ± 0.2	9.0 ± 0.3	22.0 ± 1.0
97		6.0 ± 0.2	7.0 ± 0.4	9.0 ± 0.3	24.0 ± 1.0
98		7.0 ± 0.1	7.0 ± 0.4	8.0 ± 0.4	18.0 ± 1.0
99		17.0 ± 1.0	17.0 ± 1.0	18.0 ± 0.5	30.0 ± 1.0
100		8.0 ± 0.2	7.0 ± 0.1	8.0 ± 0.5	18.0 ± 1.0
101		12.0 ± 0.5	11.0 ± 0.2	10.0 ± 0.6	21.0 ± 1.0
102		8.0 ± 0.4	7.5 ± 0.4	17.0 ± 1.0	33.0 ± 1.0
103		7.0 ± 0.1	6.5 ± 0.3	16.0 ± 0.5	28.0 ± 1.0
104		17.0 ± 1.0	13.0 ± 0.4	25.0 ± 1.0	44.0 ± 2.0
105		13.0 ± 0.8	10.0 ± 0.2	17.0 ± 0.5	35.0 ± 2.0
106		8.5 ± 0.1	6.5 ± 0.4	82.0 ± 4.0	110.0 ± 4.0
107		8.5 ± 0.3	7.0 ± 0.2	58.0 ± 2.0	76.0 ± 4.0
108		10.5 ± 0.5	11.0 ± 0.5	11.0 ± 0.5	24.0 ± 1.0
109		23.0 ± 1.0	22.0 ± 0.5	36.0 ± 2.0	55.0 ± 2.0
110		20.0 ± 0.6	23.0 ± 1.0	85.0 ± 5.0	123.0 ± 6.0
111		5.6 ± 0.3	7.0 ± 0.2	7.5 ± 0.3	18.0 ± 1.0
cisplatin		3.8 ± 0.1	3.0 ± 0.1	2.2 ± 0.1	7.7 ± 0.2

IC₅₀ values are expressed as the mean ± SD of at least three independent experiments.

Table 4. Cytotoxicity of *N*-[1-(3- or 4-trifluoromethyl)benzylimidazolidin-2-ylidene]benzenesulfonylamides **112–143** and *N*-[1-(3,5-bis(trifluoromethyl)benzylimidazolidin-2-ylidene)benzenesulfonylamides **144–157** toward human cancer cell lines and non-cancerous line HaCaT. Cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa), and the human keratinocyte cell line (HaCaT).


Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
112		15.0 ± 0.3	17.0 ± 1.0	15.5 ± 1.0	29.0 ± 1.0
113		6.0 ± 0.1	6.5 ± 0.3	15.0 ± 1.0	31.0 ± 2.0
114		5.0 ± 0.2	6.5 ± 0.3	12.0 ± 0.3	27.0 ± 1.0
115		5.5 ± 0.2	6.5 ± 0.2	12.0 ± 1.0	23.0 ± 0.5
116		6.0 ± 0.2	8.5 ± 0.3	17.0 ± 1.0	31.0 ± 2.0
117		16.0 ± 0.5	17.0 ± 1.0	12.0 ± 0.2	36.0 ± 2.0

Table 4. Cont.




Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
118		105.0 ± 4.0	10.0 ± 0.5	115.0 ± 2.0	>500
119		13.0 ± 0.4	13.5 ± 1.0	18.0 ± 1.0	41.0 ± 2.0
120		9.0 ± 0.5	11.0 ± 0.1	12.0 ± 0.5	24.0 ± 1.0
121		6.0 ± 0.1	14.0 ± 1.0	13.0 ± 1.0	24.0 ± 1.0
122		14.0 ± 0.4	20.0 ± 1.0	19.0 ± 0.5	35.0 ± 1.0
123		12.0 ± 0.5	21.0 ± 0.6	18.0 ± 1.0	30.0 ± 1.0
124		9.5 ± 0.1	10.0 ± 0.5	15.0 ± 0.2	31.0 ± 1.0
125		7.5 ± 0.2	7.5 ± 0.2	13.0 ± 0.5	25.0 ± 1.0
126		11.0 ± 0.6	21.0 ± 1.0	20.0 ± 1.0	37.0 ± 1.0
127		17.0 ± 0.5	17.5 ± 1.0	18.0 ± 1.0	39.0 ± 2.0
128		10.0 ± 0.3	14.0 ± 0.5	15.0 ± 0.4	33.0 ± 1.0
129		11.0 ± 0.1	14.0 ± 0.5	15.0 ± 1.0	31.0 ± 1.0
130		10.5 ± 0.4	8.0 ± 0.3	17.0 ± 0.5	36.0 ± 1.0
131		7.0 ± 0.2	15.0 ± 0.5	13.0 ± 0.5	25.0 ± 1.0
132		8.0 ± 0.2	17.0 ± 0.4	16.0 ± 1.0	26.0 ± 1.0
133		8.0 ± 0.3	16.0 ± 0.5	14.0 ± 1.0	25.0 ± 1.0
134		5.0 ± 0.2	11.0 ± 0.1	10.0 ± 0.6	22.0 ± 1.0
135		5.0 ± 0.2	6.5 ± 0.3	7.0 ± 0.2	19.0 ± 1.0
136		5.0 ± 0.1	6.0 ± 0.3	10.0 ± 0.4	21.0 ± 1.0
137		6.0 ± 0.2	7.0 ± 0.4	12.0 ± 0.6	21.0 ± 1.0
138		6.0 ± 0.2	9.0 ± 0.5	9.0 ± 0.6	22.0 ± 1.0
139		6.0 ± 0.1	13.0 ± 1.0	12.0 ± 1.0	24.0 ± 1.0
140		5.0 ± 0.2	10.0 ± 0.2	8.0 ± 0.5	22.0 ± 1.0
141		7.5 ± 0.2	9.5 ± 0.5	45.0 ± 2.0	180.0 ± 9.0
142		4.6 ± 0.1	6.5 ± 0.3	14.0 ± 0.2	29.0 ± 1.0
143		4.6 ± 0.1	6.0 ± 0.3	7.0 ± 0.4	19.0 ± 1.0
144		8.0 ± 0.5	8.0 ± 0.2	13.0 ± 0.2	27.0 ± 1.0
145		13.0 ± 0.5	13.0 ± 0.8	16.5 ± 1.0	36.0 ± 1.0
146		11.5 ± 0.5	12.5 ± 0.6	15.0 ± 1.0	32.0 ± 1.0
147		6.5 ± 0.3	8.0 ± 0.2	15.0 ± 1.0	28.0 ± 1.0
148		9.5 ± 0.2	8.5 ± 0.5	15.0 ± 1.0	29.0 ± 1.0
149		11.5 ± 0.6	11.0 ± 0.5	18.0 ± 1.0	33.0 ± 1.0
150		3.6 ± 0.2	4.5 ± 0.2	11.0 ± 0.3	23.0 ± 1.0
151		6.0 ± 0.1	6.0 ± 0.1	15.0 ± 1.0	28.0 ± 1.0
152		6.5 ± 0.3	6.5 ± 0.3	15.5 ± 1.0	29.0 ± 1.0
153		6.0 ± 0.3	8.0 ± 0.2	9.0 ± 0.5	19.0 ± 0.5
154		5.0 ± 0.1	6.5 ± 0.2	12.0 ± 1.0	26.0 ± 1.0
155		5.0 ± 0.1	6.0 ± 0.1	10.0 ± 0.1	19.0 ± 1.0
156		4.8 ± 0.1	7.5 ± 0.4	5.5 ± 0.2	17.0 ± 1.0
157		5.0 ± 0.1	6.0 ± 0.3	13.0 ± 0.5	23.0 ± 1.0
cisplatin		3.8 ± 0.1	3.0 ± 0.1	2.2 ± 0.1	7.7 ± 0.2

Table 5. Cytotoxicity of *N*-[1-(4-trifluoromethyl)benzyltetrahydropyrimidin-2(1*H*)-ylidene]benzene sulfonamides **158–162** toward human cancer cell lines and non-cancerous line HaCaT. Cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa), and the human keratinocyte cell line (HaCaT).

Compd	Substituent	IC ₅₀ [μM]			
		HCT-116	MCF-7	HeLa	HaCaT
158		5.0 ± 0.3	8.0 ± 0.4	6.0 ± 0.3	17.0 ± 1.0
159		9.0 ± 0.5	10.0 ± 0.3	15.5 ± 0.5	29.0 ± 1.0
160		10.5 ± 0.4	12.0 ± 0.5	8.5 ± 0.3	23.0 ± 1.0
161		6.5 ± 0.1	6.5 ± 0.2	14.0 ± 0.5	27.0 ± 1.0
162		5.5 ± 0.3	6.0 ± 0.2	12.5 ± 0.5	25.0 ± 0.7
cisplatin		3.8 ± 0.2	3.0 ± 0.1	2.2 ± 0.1	7.7 ± 0.2

IC₅₀ values are expressed as the mean ± SD of at least three independent experiments.

Table 6. Selectivity indexes (SI) of selected compounds toward cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa).

Compd	Selectivity Index (SI)		
	HCT-116	MCF-7	HeLa
48	5.5	4.7	1.3
55	5.5	3.9	3.0
62	5.3	4.5	0.3
73	5.5	3.8	2.0
114	5.4	4.1	2.2
134	4.4	2.0	2.2
140	4.4	2.2	2.7
150	6.4	5.1	2.0
157	4.6	3.8	1.7
162	4.5	4.1	2.0
cisplatin	2.0	2.5	3.5

Selectivity index: IC₅₀ value toward HaCaT cells/IC₅₀ value toward cancer cell lines.

As shown in Tables 1–5 the HCT-116 cell line presented the relatively highest susceptibility (IC₅₀ < 6.0 μM) towards the tested compounds, with the highest activity displayed by the seventeen compounds **73**, **111**, **114–115**, **134–136**, **140**, **142–143**, **150**, **154–158** and **162**. Whereas, activity against the MCF-7 cell line, with IC₅₀ in the range 4.5–6.0 μM, was observed for eight compounds (**96**, **136**, **143**, **150**, **151**, **155**, **157** and **162**), and against HeLa by five compounds (**111**, **135**, **143**, **156** and **158**), with IC₅₀ values ranging between 5.5 and 7.5 μM.

2.3. QSAR Analysis

QSAR models were constructed to find a correlation between the activity against the HCT-116 cell line and the parameters of the molecules. On the basis of the QSAR models, successive series of derivatives were designed (mainly by modifying the R¹ substituent), synthesized and evaluated in MTT tests step by step (Figure 6). As a result, the four QSAR models 1–4 have been developed in the four steps 1–4 (Table 7).




Figure 6. Scatter plots for *N*-(imidazolidin-2-ylidene)benzenesulfonamides **20–44** (**model 1**), *N*-(1-benzylimidazolidin-2-ylidene)benzenesulfonamides **45–73** (**model 2**) and *N*-[1-(4-fluorobenzyl)imidazolidin-2-ylidene]benzenesulfonamides **82–101** (**model 3**), as well as *N*-[1-(3-trifluoromethylbenzyl)imidazolidin-2-ylidene]benzenesulfonamides **112–117**, *N*-[1-(4-trifluoromethylbenzyl)imidazolidin-2-ylidene]benzenesulfonamides **118–143** and *N*-[1-[3,5-bis(trifluoromethyl)benzyl]imidazolidin-2-ylidene]benzenesulfonamides **144–157** (**model 4**) with experimental IC_{50} and predicted IC_{50} values of the training set (blue) and test set (red) for the HCT-116 cell line.

Table 7. Summary of the QSAR equations.

STEP 1	
Model 1	$R^1 = H$, compounds: 20–44 $IC_{50} = -8.783228 \text{ ast_violation} - 0.242646 \text{ PEOE_VSA-0} - 28.231708 \text{ rings} + 212.156433$ $R^2 = 0.88; R^2_{\text{adj}} = 0.85; Q^2_{\text{LOO}} = 0.80; F(3,11) = 26.76; p = 0.2 \times 10^{-4}; N_{(\text{train})} = 15; N_{(\text{test})} = 6$
STEP 2	
Model 2	$R^1 = Bn$, compounds: 45–73 $IC_{50} = 10^{0.345937 \text{ b_1rotN} + 10.490686 \text{ GCUT_PEOE}_0 + 0.507081 \text{ lip_acc} - 0.318859 \text{ radius} + 6.112894}$ $R^2 = 0.88; R^2_{\text{adj}} = 0.85; Q^2_{\text{LOO}} = 0.72; F(4,15) = 28.17; p = 0.8 \times 10^{-6}; N_{(\text{train})} = 20; N_{(\text{test})} = 7$
STEP 3	
Model 3	$R^1 = 4\text{-F-Bn}$, compounds: 82–101 $IC_{50} = 256.006020 \text{ BCUT_SMR}_1 + 0.139099 \text{ Q_VSA_HYD} - 0.120301 \text{ vsurf_V} + 201.402742$ $R^2 = 0.91; R^2_{\text{adj}} = 0.89; Q^2_{\text{LOO}} = 0.85; F(3,11) = 37.67; p = 0.4 \times 10^{-5}; N_{(\text{train})} = 15; N_{(\text{test})} = 5$
STEP 4	
Model 4	$R^1 = 3\text{-F}_3\text{C-Bn, } 4\text{-F}_3\text{C-Bn, } 3,5\text{-bis(F}_3\text{C)Bn}$, compounds: 112–157 $IC_{50} = 10^{1/(-2.44368 \text{ vsurf_CW6} + 1.59455 \text{ VDistEq} - 0.02515 \text{ vsurf_DD12} + 0.24868 \text{ vsurf_IW4} - 0.11745 \text{ vsurf_IW5} - 5.49371)}$ $R^2 = 0.84; R^2_{\text{adj}} = 0.81; Q^2_{\text{LOO}} = 0.74; F(5,25) = 26.27; p = 0.3 \times 10^{-8}; N_{(\text{train})} = 31; N_{(\text{test})} = 14$

R^2_{adj} —modified form R^2_{adj} in the test set; Q^2_{LOO} —squared correlation coefficient for the test set; F —Fisher's test; p — p -value for Fisher's test for the whole equation; $N_{(\text{train})}$ —training set; $N_{(\text{test})}$ —test set.

To compute the molecular descriptors, the energy of the molecules was minimized in the MOE software [32], using the MMFF94X force field and PM6 methods consecutively. Then, the energy was finally optimized in the GAMES software [33] using the STO3G HF

method. Such optimized structures were used to calculate 365 molecular descriptors in the MOE software. QSAR models were obtained by stepwise linear progressive regression (MLR) in the STATISTICA software [34]. Compounds with IC₅₀ outliers were removed from the analysis.

The statistical quality predictive ability of the QSAR models was evaluated using the coefficient of determination R² and modified coefficients R²_{adj} and Q²_{LOO}. Additionally, for each model, the residuals were normally distributed. The minimal value of the parameters were: R²_{adj} greater than 0.85 and Q²_{LOO} greater than 0.72, where, in the test set for each model, there was a minimum of 25% compounds.

The QSAR **Model 1** for compounds **20–44** (R¹ = H) (Table 7, Figure 6) shows that the activity for the HCT-116 cell line correlates with higher values of descriptors related to atom counts and bond counts, *ast_violation*, and partial charge *PEOE_VSA-0* as well as the number of rings in the molecule *rings* (Table 8). Taking into account a residue analysis for the obtained model, it is noted that a high correlation coefficient of 89% is observed for the *rings* descriptor and the IC₅₀ value for the HCT-116 cell line. To conclude, the model shows that, if the number of rings in the molecule increases, the IC₅₀ value for the HCT-116 cell line will decrease. Based on this observation, compounds with one and two more rings, **45–73** (R¹ = Bn) and **74–81** (R¹ = 2-(naphtalen-2-yl)methyl group), were synthesized and investigated for their cytotoxic activity. The obtained experimental data were used to build a following model describing the quantitative structure–activity relationships.

Table 8. Type and chemical meaning of molecular descriptors in QSAR models.

	Descriptor	Type	Definition
Model 1	ast_violation	The atom count and bond count descriptors	Number of Astex fragment-likeness violations
	PEOE_VSA-0	Partial charge descriptor	Sum of the van der Waals area, where the partial charge is in the range −0.05 to 0.50
	rings	The atom count and bond count descriptors	The number of rings in molecule
Model 2	b_1rotN	The atom count and bond count descriptors	Number of rotatable single bonds. Conjugated single bonds are not included (e.g. ester and peptide bonds)
	GCUT_PEOE_0	Adjacency and distance matrix descriptors	The smallest GCUT descriptor using partial PEOE loads. The descriptor is related to the distance between the atoms and the charge of the atoms
	lip_acc	The atom count and bond count descriptors	The number of oxygen and nitrogen atoms
	radius	Adjacency and distance matrix descriptors	The descriptor is related to the distance between atoms and the surrounding atoms by other atoms
Model 3	BCUT_SMR_1	Adjacency and distance matrix descriptors	The BCUT descriptors using atomic contribution to molar refractivity (using the Wildman and Crippen SMR method) instead of partial charge.
	Q_VSA_HYD vsurf_S	Partial charge descriptors Surface area, volume and shape descriptors	Total hydrophobic van der Waals surface area. Interaction field surface area
Model 4	vsurf_CW6	Capacity factor	The descriptor is depend on the structure of molecule, connectivity and configuration of atoms
	VDistEq	Adjacency and distance matrix descriptor	The descriptor VDistEq is information content index of vertex distance equality.
	vsurf_DD12	Adjacency and distance matrix descriptor	The descriptor quantifies the contact distance of lowest and the 2nd lowest hydrophobic energy points of a molecule
	vsurf_IW4 vsurf_IW5	Partial charge descriptor Partial charge descriptor	Hydrophilic interaction energy moment Hydrophilic interaction energy moment

In the second step, QSAR **Model 2** for compounds **45–73** ($R^1 = \text{Bn}$) (Table 7, Figure 6) indicated that the IC_{50} value depends on the number of rotatable single bonds b_1rotN , the distance between the atoms and the charge of atoms $GCUT_PEOE_0$, the number of oxygen and nitrogen atoms lip_acc and the descriptor related to the distance between atoms and the surrounding atoms by other atoms $radius$ (Table 8). It was observed that the predictor that corresponded most with antitumor activity for the HCT-116 model was the lip_acc descriptor, with a correlation coefficient of 70%. Based on this information, it was decided to synthesize compounds with one fluorine atom and one bromide atom in benzyl ring, compounds **82–101** ($R^1 = 4\text{-F-Bn}$) and **102–111** ($R^1 = 4\text{-Br-Bn}$), respectively. **Model 2** allowed us to obtain series of compounds with interesting cytotoxic effects that were used to perform new QSAR calculations in **Step 3**.

The following QSAR **Model 3** for compounds **82–101** ($R^1 = 4\text{-F-Bn}$) (Table 7, Figure 6) paid attention to low values of descriptors related to adjacency and distance matrix $BCUT_SMR_1$ as well as to total hydrophobic van der Waals surface area Q_VSA_HYD , which have beneficial impacts on high anticancer activity. The negative coefficient of the $vsurf_S$ descriptor shows that a high value for the interaction field surface area is valuable for anticancer activity (Table 8). The residual analysis for **Model 3** indicated the best correlation coefficient for the Q_VSA_HYD descriptor. Based on this conclusion, in **Step 4** we decided to increase the hydrophobicity of compounds by replacing the fluorine atom with one and two trifluoromethyl groups in the benzyl ring. Consequently, in the next steps, compounds **112–117** ($R^1 = 3\text{-F}_3\text{C-Bn}$), **118–143** ($R^1 = 4\text{-F}_3\text{C-Bn}$) and **144–157** ($R^1 = 3,5\text{-bis(F}_3\text{C)Bn}$) were synthesized.

Based on the analysis of the QSAR equations, the series of above-described derivatives were designed and synthesized consistently step by step. Each synthesized series of compounds followed the previously drawn conclusions from the generated QSAR models. In this way, the most active series against the HCT-116 cell line **112–117** ($R^1 = 3\text{-F}_3\text{C-Bn}$), **118–143** ($R^1 = 4\text{-F}_3\text{C-Bn}$) and **144–157** ($R^1 = 3,5\text{-bis(F}_3\text{C)Bn}$) were achieved successfully. Additionally, compound **150** turned out to be the most prominent anticancer agent towards colorectal and breast tumors, exhibiting IC_{50} values of 3.6 μM for HCT-116 and 4.5 μM for the MCF-7 cell line.

The presented QSAR **Model 4** for compounds **112–117** ($R^1 = 3\text{-F}_3\text{C-Bn}$), **118–143** ($R^1 = 4\text{-F}_3\text{C-Bn}$) and **144–157** ($R^1 = 3,5\text{-bis(F}_3\text{C)Bn}$) (Table 7, Figure 6) indicated three descriptors connected with the hydrophobicity of compounds, $vsurf_DD12$, $vsurf_IW4$ and $vsurf_IW5$ (Table 8). High values of $vsurf_IW4$ and low values of $vsurf_IW5$ and $vsurf_DD12$ favorably influence the cytotoxic activity toward the HCT-116 cell line.

2.4. SAR Analysis

Compounds containing 1,4-disubstituted piperazine rings at the R^2 position are generally more active for the HCT-116 and MCF-7 cell lines. Comparison of a series containing the $R^2 = 4\text{-phenylpiperazin-1-yl}$ substituent (**31**, **57**, **92**, **106**, **131** and **150**) with a similar series bearing the $R^2 = \text{PhNH}$ group (**25**, **50**, **85**, **104**, **122** and **146**) clearly shows this advantage in activity (Table 9). We also found that the nature of the R^1 substituent exerted a strong influence on the anticancer activity of the discussed compounds. Thus, replacement in both series of $R^1 = \text{H}$ (**31**, **25**) by the $R^1 = \text{benzyl}$, 4-F-benzyl, 4-Br-benzyl, 4-(trifluoromethyl)benzyl or 3,5-bis(trifluoromethyl)benzyl moieties consequently leads to a significant increase in activity (Table 9).

Moreover, the activity of compounds containing the $R^2 = 4\text{-phenylpiperazin-1-yl}$ moiety depends significantly on the position and nature of the substituent of the phenyl ring. For example, compounds bearing the $R^2 = 4\text{-(4-trifluoromethyl)phenylpiperazin-1-yl}$ moiety (**34**, **60** and **134**) show slightly weaker activity compared to the series comprising the trifluoromethyl group in 3 position (**35**, **61** and **135**) (Table 10). Although the presence of the substituted phenyl moiety attached to the piperazine ring positively affects the activity, it should be noted that, in some cases, a loss of activity was noted, e.g., **67** ($R^2 = 4\text{-(4-nitrophenyl)piperazin-1-yl}$), **70** ($R^2 = 4\text{-(phenylsulfonyl)piperazin-1-yl}$) or **71**


(R² = 4-tosylpiperazin-1-yl) with IC₅₀ (HCT-116) 168.0, 300.0 and 155.0 μM, IC₅₀ (MCF-7) 153.0, 490.0 and 205.0 μM and IC₅₀ (HeLa) 140.0, 550.0 and 265.0 μM, respectively (Tables 1–5).

Table 9. Comparison of IC₅₀ value for the HCT-116 and MCF-7 cell lines for compounds **31**, **57**, **92**, **106**, **131**, **150**, with the substituent R² = 4-phenylpiperazin-1-yl, and compounds **25**, **50**, **85**, **104**, **122**, **146**, with the substituent R² = phenylamino.

Compd	31	57	92	106	131	150
R ¹ =	H	Bn	4-F-Bn	4-Br-Bn	4-F ₃ C-Bn	3,5-bis(F ₃ C)Bn
R ² =	4-Ph-piperazin-1-yl					
IC ₅₀ [μM]						
HCT-116	45.0	8.0	7.0	8.5	7.0	3.6
MCF-7	46.0	8.0	8.0	6.5	15.0	4.5
Compd	25	50	85	104	122	146
R ¹ =	H	Bn	4-F-Bn	4-Br-Bn	4-F ₃ C-Bn	3,5-bis(F ₃ C)Bn
R ² =	PhNH					
IC ₅₀ [μM]						
HCT-116	45.0	18.0	15.0	17.0	14.0	11.5
MCF-7	46.0	43.0	23.0	13.0	20.0	12.5

Table 10. Comparison of IC₅₀ values for the HCT-116, MCF-7 and HeLa cell lines for compounds **34**, **60**, **134**, with R² = S = 4-[4-(trifluoromethyl)phenyl]piperazin-1-yl, and compounds **35**, **61**, **135**, with R² = T = 4-[3-(trifluoromethyl)phenyl]piperazin-1-yl.

Compd	34	35	60	61	134	135
R ¹ =	H	H	Bn	Bn	4-F ₃ C-Bn	4-F ₃ C-Bn
R ² =	S	T	S	T	S	T
IC ₅₀ [μM]						
HCT-116	18.0	14.0	8.0	6.5	5.0	5.0
MCF-7	12.0	16.0	14.0	9.0	11.0	6.5
HeLa	24.0	16.0	9.0	10.0	10.0	7.0



2.5. Investigation of the Mechanism of Antiproliferative Activity

2.5.1. MDM2 and p53 Protein Levels

Structural analogs of the examined compounds were found to bind into the p53-binding pocket of the MDM2 protein. Thus, the effects of the examined compounds on the inhibition of MDM2-p53 interactions were examined. MDM2 and p53 protein levels were determined with Western blot analysis after the treatment of MCF-7 cells with compounds selected for their high selectivity index (**48**, **62**, **134**, **138**, and **140**). Compounds were examined at different concentrations (4 μM and 10 μM) following a 24-h incubation (Figure 7). Western blot analysis revealed no changes in either MDM2 or p53 levels, indicating that p53 stability does not change upon compound treatment.




Figure 7. Effects on MDM2 and p53 protein levels upon treatment. Western blot analysis showing MDM2 and p53 protein levels in MCF-7 cells, untreated and treated with the indicated compounds in concentrations 4 μ M (A) and 10 μ M (B) for 24 h. Reference: β -tubulin.

2.5.2. Cell Cycle Analysis

P53 controls cell proliferation through the regulation of the cell cycle. In order to determine p53-independent cell cycle arrest, the influence of selected compounds on the cell cycle distribution in MCF-7 cells was analyzed. Cells were treated with a concentration range of two selected compounds (140 and 48) for 48 h. Cell cycle distribution was analyzed with flow cytometry. In the case of compound 48, a significant increase in the G0/G1 phase of the cell cycle was observed at a concentration of 10 μ M, while a concentration-dependent increase in the sub-G1 population of the cell cycle was observed, indicating possible apoptosis induction. Compound 140 at the lower concentration of 10 μ M increased the G0/G1 population, whereas at the higher examined concentration of 25 μ M, an increase in the G2/M phase of the cell cycle was observed. Alongside G0/G1 and G2/M arrest, a concentration-dependent increase in the sub-G1 fraction of the cell cycle was observed upon treatment with compound 140. However, a higher increase in the sub-G1 population was observed in compound-48-treated cells (Figure 8).

2.5.3. Cytotoxic Activity toward Wild-Type and Mutant p53 Cell Lines

Cell cycle analysis showed a p53-independent mechanism of action for the examined compounds. Thus, the ability of the selected compounds to exert cytotoxic activity toward cell lines harboring mutant p53 was examined. Compounds displaying a high selectivity index (Table 6) were selected for the analysis of their activity toward ovarian and breast cancer cells with wild-type p53 (A2780, MCF-7) and mutant p53 (SKOV-3, T47D). The results of the MTT assay showed cytotoxic activity exerted by the compounds toward both types of cells (Table 11).

Table 11. Cytotoxicity of compounds 48, 62, 134, 138 and 140 toward ovarian cancer (A2780, SKOV-3) and breast cancer (MCF-7, T47D) cell lines.

Compd	Substituent	IC ₅₀ [μ M]				
		A2780	SKOV3	MCF-7	T47D	HaCaT
48		4.0 \pm 0.1	8.1 \pm 0.1	7.8 \pm 0.1	4.8 \pm 0.1	25.0 \pm 1.0
62		3.9 \pm 0.1	10.1 \pm 0.1	10.4 \pm 0.1	4.9 \pm 0.1	32.0 \pm 1.0
134		3.9 \pm 0.1	5.7 \pm 0.1	7.8 \pm 0.1	3.2 \pm 0.1	22.0 \pm 1.0
138		2.2 \pm 0.1	5.8 \pm 0.1	8.2 \pm 0.1	4.4 \pm 0.1	22.0 \pm 1.0
140		4.5 \pm 0.1	6.6 \pm 0.1	6.9 \pm 0.1	5.3 \pm 0.1	22.0 \pm 1.0
cisplatin		1.4 \pm 0.1	71.0 \pm 0.1	3.0 \pm 0.1	3.1 \pm 0.1	7.7 \pm 0.2

IC₅₀ was determined following 72 h of incubation. IC₅₀ values are expressed as the mean \pm SD of at last three independent experiments.




Figure 8. Cell cycle arrest in MCF-7 cells induced by compounds **48** and **140**. Cells were treated with the indicated concentrations of the compounds, and the cell cycle distribution was analyzed with flow cytometry. **(A)** Histograms showing the distribution of cell populations in the sub-G1, G0/G1, S and G2/M phases of the cell cycle. **(B)** Graphs demonstrating the percentages of cells in the depicted phases of the cell cycle. Values represent the mean \pm SD of three independent experiments. Data were analyzed by one-way ANOVA with Tukey's post hoc test [$p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***)].

2.5.4. Apoptosis Induction Analysis

The increase in the sub-G1 fraction of the cell cycle by compounds **140** and **48** suggested apoptosis induction. To confirm this, MCF-7 cells were treated with a concentration range of compounds **140** and **48** for 72 h. Flow cytometric analysis was performed with Annexin V-PE staining. The results showed a concentration-dependent increase in the apoptotic population of cells induced by the treatment with both compounds. The increase in apoptotic cells was mainly evident in the late apoptotic stage (upper right quadrant) (Figure 9).

Since the examined compounds exerted cytotoxic activity toward cell lines harboring mutant p53, the ability of compounds **140** and **48** to induce apoptosis in T47D cells with mutant p53 was examined. Similarly, as in the case of MCF-7 cells, a concentration-dependent increase in apoptotic cells was induced in T47D cells. Cell death was induced to a similar extent in cells harboring wild-type and mutant p53 (Figure 10).




Figure 9. Induction of apoptosis by compounds **48** and **140** in MCF-7 cells. Cells were treated with the indicated concentrations of compounds **48** and **140** for 72 h, stained with Annexin V-PE and 7-AAD and analyzed with flow cytometry. (A) Dot plots showing early apoptotic (bottom right quadrant), late apoptotic (upper right quadrant), viable (lower left quadrant) and necrotic cell populations (upper left quadrant). (B) Graphs indicating early and late apoptotic cells. Values represent the mean \pm SD of three repetitions. Data were analyzed by one-way ANOVA with Tukey's post hoc test [$p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***)].

2.5.5. Discussion

To discern the mechanism of activity of the studied compounds, cell cycle arrest and apoptosis induction, associated with the activation of the p53 tumor suppressor protein, were analyzed. Our previous research showed that structural analogs of the compounds examined in the presented research bind into the p53-binding pocket of MDM2 protein [17]. This suggests possible induction of apoptosis by a mechanism similar to that of Nutlin-3a, a selective inhibitor of MDM2-p53 interactions. MDM2 is a promising target for developing anti-cancer therapies since it is as an important negative regulator of the p53 protein [35,36]. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, limiting the p53 growth-suppressive function in unstressed cells. In these cells, MDM2 constantly monoubiquitinates p53 and thus is a critical step in mediating its degradation by nuclear and cytoplasmic proteasomes [37]. To explore the possibility that the observed cytotoxicity of the analyzed compounds results from their ability to block MDM2-p53 interactions and subsequently inhibit MDM2-mediated p53 degrada-

tion, p53 protein levels were examined by Western blot. An increase in p53 levels after treatment would signify its stabilization and promotion of cell death. The results of our analysis showed no change in p53 stability. However, cell cycle arrest and apoptosis were determined upon treatment with the examined compounds. These results pointed to a p53-independent mechanism of cell death induction.




Figure 10. Induction of apoptosis by compounds 48 and 140 in T47D cells. Cells were treated with the indicated concentrations of compounds 48 and 140 for 72 h, stained with Annexin V-PE and 7-AAD, and analyzed with flow cytometry. (A) Dot plots showing early apoptotic (bottom right quadrant), late apoptotic (upper right quadrant), viable (lower left quadrant) and necrotic cell populations (upper left quadrant). (B) Graphs indicating early and late apoptotic cells. Values represent the mean \pm SD of three repetitions. Data were analyzed by one-way ANOVA with Tukey's post hoc test [$p < 0.01$ (**), $p < 0.001$ (***)].

The p53 pathway is an important target in cancer drug design. In cancers with wild-type p53, MDM2 inhibitors have found clinical application. However, in the case of tumors with mutant p53, targeting strategies are more challenging. Fifty percent of tumors harbor mutated or deleted p53, which leads to not only loss of p53 tumor suppressor functions, but also to gain-of-function driving tumor cell proliferation. Mutant p53 tumors display a more aggressive phenotype than their counterpart tumors harboring wild-type p53. Targeting strategies for mutant p53 tumors include reactivation of p53. However, direct targeting of mutant p53 is challenging due to its structural diversity. Thus, compounds inducing

cell death in mutant p53 tumors can be considered important candidates in the treatment of cancers [38–40].

The results of the presented research showed cell death induction by compounds **48** and **140** in breast cancer cell lines harboring wild-type p53 (MCF-7 cells) and mutant p53 (T47D cells). Compounds **48** and **140** induced apoptosis in T47D cells to a similar extent as in MCF-7 cells. Research has shown that the p53 mutation in T47D cells facilitates cell survival [41]. This is associated with the disruption of signaling pathways controlled by wild-type p53 and induced by a p53 mutation, which leads to the activation of various compensatory mechanisms required to support tumor cell survival [40]. Thus, targeting signaling pathways activated by mutant p53 is a promising therapeutic strategy. Further research regarding the mechanism of cell death induced by the examined compounds could address the pharmacological value of these compounds.

3. Materials and Methods

3.1. General Information

The following instruments and parameters were used: Melting points were measured using a Stuart SMP30 (Bibby Scientific Limited, Stone Staffordshire UK) apparatus. IR spectra: KBr pellets, spectra were made on a Thermo Mattson Satellite FTIR spectrophotometer in the range 400–4000 cm^{-1} . ^1H NMR and ^{13}C NMR spectra were obtained on a Varian Unity Plus 500 apparatus (Varian, Palo Alto, CA, USA) at 500 MHz, chemical shifts are expressed in parts per million (ppm) relative to (Me_4Si) TMS as an internal standard. Elemental analyses for C, H and N were obtained on a CHN Elemental Analyzer (Perkin Elmer, Shelton, CT, USA) and obtained values are in agreement with the theoretical values within the $\pm 0.4\%$ range. Thin-Layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 Plates (Merck, Darmstadt, Germany) and visualized with UV. High-resolution mass spectrometry (HRMS) was conducted on a TripleTOF 5600+ mass spectrometer (AB SCIEX, Framingham, MA, USA) equipped with a DuoSprayTM Ion Source and coupled with a Micro HPLC system EkspertTM microLC 200 (Eksigent Redwood City, CA, USA); Column: HALO Fused-Core C18 (50 \times 0.5 mm, 2.7 μm) (Eksigent), thermostated at 50 $^\circ\text{C}$; Flow: 30 $\mu\text{L}/\text{min}$; Mobile Phase: A: 0.1% formic acid in water, B: 0.1% formic acid in acetonitrile; Isocratic program 100% B, 4 min. Moreover, a MALDI-TOF/TOF 5800 Sciex spectrometer was used to analyze the remaining obtained compounds. Samples were dissolved in methanol with 5% water content, and ferulic acid (FA, concentration 10 mg/mL in 33% acetonitrile/17% formic acid in water) was used as the matrix. Briefly, 0.8 microl of the sample was mixed on a measuring plate (Opti-TOF 384 MALDI plate insert) with 0.8 microl of the matrix and was allowed to crystallize freely at room temperature. Then, the plate was introduced into the spectrometer, and the measurements were carried out in reflector positive ion mode at a constant laser intensity. The commercially unavailable starting materials were obtained according to the following methods previously described: **1** [42], **2** [23] and **3** [24].

3.2. Synthesis

The procedures for the preparation of compounds **4–162** are provided in the Supplementary Materials (S.3.2. Synthesis).

3.3. X-ray Structure Determination

Crystal structures were investigated on an IPDS 2T dual beam diffractometer (STOE & Cie GmbH, Darmstadt, Germany). The crystal structure was solved using intrinsic phasing implemented in SHELXT and refined anisotropically using the program packages Olex2 [43] and SHELX-2015 [44,45]. Crystallographic data reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication No. CCDC 2154790 for **27**. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures (accessed on 25 February 2022).

3.4. Cytotoxic Activity Screening and Determination of Mode Cell Death Induction

3.4.1. Cell Culture

All chemicals, if not stated otherwise, were obtained from Sigma–Aldrich (St. Louis, MO, USA). The HCT-116 cell line was purchased from ATCC (ATCC-No: CCL-247), while the MCF-7, HeLa and HaCaT cell lines were purchased from Cell Lines Services (Eppelheim, Germany). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin. Cultures were maintained in a humidified atmosphere with 5% carbon dioxide at 37 °C in an incubator (Heraceus, HeraCell).

3.4.2. Cell Viability Assay

Cell viability was examined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. Cells were seeded in 96-well plates at a density of 3×10^3 cells/well and treated for 72 h with the tested compounds in the concentration range of 1–100 µM. Then, MTT (0.5 mg/mL) was added to the medium and cells were further incubated for 2 h at 37 °C. In the next stage, cells were lysed with DMSO and the absorbance of the formazan solution was measured at 550 nm with a plate reader (1420 multilabel counter, Victor, Jügesheim, Germany). The experiment was performed in triplicate. Values are expressed as the mean \pm SD of at least three independent experiments. Cisplatin was used as a positive control.

Compounds **48**, **62**, **134**, **138** and **140** were further examined toward MCF7 (breast cancer cell line, ATCC, HTB-22), T47D (breast cancer cell line, DSMZ ACC 739), A2780 (ovarian carcinoma cell line, ECACC, 93112519), and SKOV3 (ovarian carcinoma cell line, ATCC, HTB-77) cells. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific).

3.4.3. Determination of Protein Levels with Western Blot

Protein extracts were heat-denatured (95 °C) in Laemmli buffer (50 mM Tris/HCl, 0.01% Bromophenol Blue, 1.75% 2-mercaptoethanol, 11% glycerol, 2% SDS) and separated by 10–12% SDS/PAGE electrophoresis. Proteins were transferred to an Immobilon-P PVDF membrane (Merck Millipore, Burlington, MA, USA). The membranes were incubated for 1 h using 5% low-fat milk solution in $1 \times$ TBS (50 mM Tris-Cl, pH 7.5, 150 mM NaCl) as a blocking buffer and then overnight at 4 °C in the same blocking solution containing one of the following antibodies: anti-MDM2 (rabbit, Sigma-Aldrich AB-166, Burlington, MA, USA), anti-p53 (rabbit, Sigma-Aldrich S15) or α -tubulin (rabbit, 11H10, Cell Signaling, Danvers, MA, USA). After washing (3×10 min in TBS), membranes were incubated for 2 h in room temperature with the adequate HRP-conjugated secondary antibody: goat anti-rabbit IgG (1:5000, Abcam, Cambridge, UK; cat. 97051). Membranes were developed using an HRP detection kit WesternBright Quantum (Advansta, San Jose, CA, USA; cat. K-12042).

3.4.4. Cell Cycle Analysis

Cell cycle distribution was analyzed with flow cytometry analysis with PI staining. MCF-7 cells were treated with compounds **48** and **140** (5, 10, 25 µM) for 48 h. Following treatment, the cells were collected and fixed in cold 70% ethanol for 24 h. The fixed cells were washed with PBS and incubated with 100 µg/mL RNase (Invitrogen, Germany) and stained with 10 µg/mL PI (Invitrogen, Germany) for 30 min at RT. A total of 10^4 cells were examined with a FACSCalibur cytometer (BD) and data was analyzed with Flowing software (version 2.5).

3.4.5. Apoptosis Analysis

Levels of apoptosis were measured by flow cytometry using the Annexin V-PE Apoptosis Detection Kit I (BD Biosciences, Belgium) according to the manufacturer's instructions. Apoptosis was assessed after a 72 h treatment of MCF7 and T47D cells with compounds

48 and **140** in the concentrations of 5, 10 and 25 μM . Proceeding cell treatment, cells were collected, washed with PBS and stained with Annexin V-phycoerythrin (PE) and 7-amino-actinomycin (7-AAD) in Annexin V binding buffer for 15 min at RT in the dark. After staining, cells were diluted in Annexin V binding buffer and analyzed on a BD FACSCalibur flow cytometer (BD Biosciences). At total of 10^4 cells were analyzed from each sample and data were analyzed with Flowing software (version 2.5).

3.4.6. Statistical Analysis

Values are expressed as means \pm SD of at least three independent experiments. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad software). Differences between control and treated samples were analyzed by one-way ANOVA with Tukey's post hoc tests. A p value of <0.05 was considered as statistically significant in each experiment.

3.5. Calculation of Molecular Descriptors and Generation of QSAR Models

Molecular descriptors were calculated in MOE 2019.01 software. Statistical analysis was carried out used TIBCO STATISTICA software 13.3.

4. Conclusions

We have synthesized a series of 2-[(4-amino-6-*N*-substituted-1,3,5-triazin-2-yl)methylthio]-*N*-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide **20–157** and 2-[(4-amino-6-substituted-1,3,5-triazin-2-yl)methylthio]-*N*-{1-[4-(trifluoromethyl)benzyl]tetrahydropyrimidin-2(1*H*)-ylidene}-4-chloro-5-methylbenzenesulfonamides derivatives **158–162** using cyclocondensation reactions of the 1,3,5-triazine moiety from previously obtained ethyl 2-[2-[*N*-(imidazolidin-2-ylidene)sulfamoyl]-5-chloro-4-methylphenylthio]acetate **11–18** and appropriate biguanide hydrochloride. The molecular structures of most compounds were confirmed by elemental analyses, and, for all compounds, NMR and IR spectroscopic methods were employed. For the representative compound **27**, an X-ray structure was determined.

The designing and development of new structures were supported with QSAR analysis. QSAR models were constructed in four steps and led to modification of the *N*-1 position of imidazolidine ring with benzyl, halogen-substituted benzyl and trifluoromethylbenzyl (3- F_3C -Bn, 4- F_3C -Bn, and 3,5-bis(F_3C)Bn) groups consistently. Consequently, improvement of cytotoxic activity against the HCT-116 cell line was achieved and the highest cytotoxic activity was presented by series **112–117** ($R^1 = 3\text{-F}_3\text{C}\text{-Bn}$), **118–143** ($R^1 = 4\text{-F}_3\text{C}\text{-Bn}$) and **144–157** ($R^1 = 3,5\text{-bis}(\text{F}_3\text{C})\text{Bn}$).

All obtained compounds **20–162** were investigated on three tumor cell lines: colon cancer (HCT-116), breast cancer (MCF-7), cervical cancer (HeLa) and non-cancerous keratinocyte cell line (HaCaT). Compounds containing the substituent $R^1 = 3,5\text{-bis}(\text{trifluoromethyl})\text{benzyl}$ showed the highest cytotoxic activity against the tested cancer lines. Compounds from the series of derivatives containing the substituents $R^1 = 3,5\text{-bis}(\text{trifluoromethyl})\text{benzyl}$ and $R^1 = 4\text{-trifluoromethylbenzyl}$ showed the highest cytotoxic activity against the tested cancer lines, with IC_{50} values ranging from 3.6 μM to 11.0 μM . Compounds **48** $R^1 = \text{benzyl}$ ($\text{IC}_{50\text{HCT-116, MCF-7}} = 6.0$ and 7.0 μM ; $\text{SI}_{\text{HCT-116, MCF-7}} = 5.5$ and 4.7) and **140** $R^1 = 4\text{-trifluoromethylbenzyl}$ ($\text{IC}_{50\text{HCT-116, HeLa}} = 5.0$ and 8.0 μM ; $\text{SI}_{\text{HCT-116, HeLa}} = 4.4$ and 2.7) were shown to induce cell cycle arrest in the G₀/G₁ and G₂/M phases of the cell cycle. Furthermore, apoptosis was induced in wt-p53 and mutant p53 cells in a p53-independent manner. The indicated selectivity index in comparison to the control compound as well as the established mechanism of activity shows the promising potential of the utilized scaffolds in this research for anticancer compound design.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms23137178/s1>.

Author Contributions: Ł.T. and J.S. created the concept and designed the study; Ł.T. performed the synthesis of compounds; Ł.T., J.S., B.Ż. and A.K., wrote the manuscript; Ł.T. and K.S. generated the QSAR models; Ł.T., J.S. and B.Ż. carried out interpretation of the QSAR models; A.K. tested the cytotoxic activity toward HCT-116, MCF-7, HeLa and HaCaT cell lines for all obtained compounds and performed flow cytometry analysis and data analysis; J.C. performed crystallographic analysis; E.A.G. and R.K. performed Western blot analysis and cytotoxicity analysis towards A2780, SKOV-3, MCF-7 and T47D cell lines for five selected compounds and performed data analysis. All the authors discussed the results of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The study was supported by the project POWR.03.02.00-00-I026/17-00, co-financed by the European Union through the European Social Fund under the Operational Programme Knowledge Education Development 2014–2020. Financial support of these studies from Gdańsk University of Technology by the DEC-2/2021/IDUB/V.6/Si grant under the SILICIUM SUPPORTING CORE R&D FACILITIES—‘Excellence Initiative—Research University’ program is gratefully acknowledged.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are available as Supplementary Materials.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Health Organization (WHO). Fact Sheet: Cancer. Available online: <https://www.who.int/news-room/fact-sheets/detail/cancer> (accessed on 3 February 2022).
2. Arruebo, M.; Vilaboa, N.; Sáez-Gutierrez, B.; Lambea, J.; Tres, A.; Valladares, M.; González-Fernández, Á. Assessment of the evolution of cancer treatment therapies. *Cancers* **2011**, *3*, 3279–3330. [[CrossRef](#)] [[PubMed](#)]
3. Cui, Q.; Wang, J.-Q.; Assaraf, Y.G.; Ren, L.; Gupta, P.; Wei, L.; Ashby, C.R.; Yang, D.H.; Chen, Z.-S. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resist. Updates* **2018**, *41*, 1–25. [[CrossRef](#)] [[PubMed](#)]
4. Cui, Q.; Yang, Y.; Ji, N.; Wang, J.-Q.; Ren, L.; Yang, D.-H.; Chen, Z.-S. Gaseous signaling molecules and their application in resistant cancer treatment: From invisible to visible. *Future Med. Chem.* **2019**, *11*, 323–336. [[CrossRef](#)] [[PubMed](#)]
5. Hong, X.; Li, Z.-X.; Hou, J.; Zhang, H.-Y.; Zhang, C.-Y.; Zhang, J.; Sun, H.; Pang, L.-H.; Wang, T.; Deng, Z.-H. Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells. *BMC Cancer* **2021**, *21*, 33. [[CrossRef](#)] [[PubMed](#)]
6. Subbiah, V.; Kreitman, R.J.; Wainberg, Z.A.; Cho, J.Y.; Schellens, J.H.M.; Soria, J.C.; Wen, P.Y.; Zielinski, C.; Cabanillas, M.E.; Urbanowitz, G.; et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. *J. Clin. Oncol.* **2018**, *36*, 7–13. [[CrossRef](#)]
7. Curigliano, G.; Criscitiello, C.; Esposito, A.; Fumagalli, L.; Gelao, L.; Locatelli, M.; Minchella, I.; Goldhirsch, A. Best management of locally advanced inoperable breast cancer. *EJC Suppl.* **2013**, *11*, 289–290. [[CrossRef](#)]
8. Onuma, A.E.; Zhang, H.; Huang, H.; Williams, T.M.; Noonan, A.; Tsung, A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. *Gene Expr.* **2020**, *20*, 53–65. [[CrossRef](#)]
9. Kim, G.; McKee, A.E.; Ning, Y.M.; Hazarika, M.; Theoret, M.; Johnson, J.R.; Xu, Q.C.; Tang, S.; Sridhara, R.; Jiang, X.; et al. FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. *Clin. Cancer Res.* **2014**, *20*, 4994–5000. [[CrossRef](#)]
10. ClinicalTrials.gov Identifier: NCT04790448. Available online: <https://clinicaltrials.gov/ct2/show/NCT04790448?cond=NCT04790448&draw=2&rank=1> (accessed on 10 March 2021).
11. ClinicalTrials.gov Identifier: NCT02314481. Available online: <https://clinicaltrials.gov/ct2/show/NCT02314481?cond=NCT02314481&draw=2&rank=1> (accessed on 11 December 2014).
12. ClinicalTrials.gov Identifier: NCT00073138. Available online: <https://clinicaltrials.gov/ct2/show/NCT00073138?cond=NCT00073138&draw=2&rank=1> (accessed on 18 November 2003).
13. Kim, E.S. Enasidenib: First Global Approval. *Drugs* **2017**, *77*, 1705–1711. [[CrossRef](#)]
14. ClinicalTrials.gov Identifier: NCT03911973, NCT03698383. Available online: <https://clinicaltrials.gov/ct2/show/NCT03911973?cond=NCT03911973&draw=2&rank=1> (accessed on 11 April 2019).
15. ClinicalTrials.gov Identifier: NCT03065062. Available online: <https://clinicaltrials.gov/ct2/show/NCT03065062?cond=NCT03065062&draw=2&rank=1> (accessed on 27 February 2017).

16. Sławiński, J.; Żołnowska, B.; Orlewska, C.; Chojnacki, J. Synthesis and molecular structure of novel 2-(alkylthio)-4-chloro-N-(4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-5-methylbenzenesulfonamides with potential anticancer activity. *Mon. Chem.* **2012**, *143*, 1705–1718. [[CrossRef](#)]
17. Tomorowicz, Ł.; Sławiński, J.; Żołnowska, B.; Szafranski, K.; Kawiak, A. Synthesis, Antitumor Evaluation, Molecular Modeling and Quantitative Structure-Activity Relationship (QSAR) of Novel 2-[(4-Amino-6-N-substituted-1,3,5-triazin-2-yl)methylthio]-4-chloro-5-methyl-N-(1H-benzo[d]imidazol-2(3H)-ylidene)benzenesulfonamides. *Int. J. Mol. Sci.* **2020**, *21*, 2924. [[CrossRef](#)] [[PubMed](#)]
18. Pogorzelska, A.; Sławiński, J.; Kawiak, A.; Żołnowska, B.; Chojnacki, J.; Stasiłojć, G.; Ulenberg, S.; Szafranski, K.; Bączek, T. Synthesis, molecular structure, and metabolic stability of new series of N'-(2-alkylthio-4-chloro-5-methylbenzenesulfonyl)-1-(5-phenyl-1H-pyrazol-1-yl)amidine as potential anti-cancer agents. *Eur. J. Med. Chem.* **2018**, *155*, 670–680. [[CrossRef](#)] [[PubMed](#)]
19. Bułakowska, A.; Sławiński, J.; Siedlecka-Kroplewska, K.; Stasiłojć, G.; Serocki, M.; Heldt, M. Novel N-(aryl/heteroaryl)-2-chlorobenzenesulfonamide derivatives: Synthesis and anticancer activity evaluation. *Bioorg. Chem.* **2020**, *104*, 104309. [[CrossRef](#)] [[PubMed](#)]
20. Worachartcheewan, A.; Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. QSAR study of amidino bis-benzimidazole derivatives as potent anti-malarial agents against *Plasmodium falciparum*. *Chem. Pap.* **2013**, *67*, 1462–1473. [[CrossRef](#)]
21. Worachartcheewan, A.; Prachayasittikul, S.; Pingaew, S.; Nantasenamat, C.; Tantimongcolwat, T.; Ruchirawat, S.; Prachayasittikul, V. Antioxidant, cytotoxicity, and QSAR study of 1-adamantylthio derivatives of 3-picoline and phenylpyridines. *Med. Chem. Res.* **2012**, *21*, 3514–3522. [[CrossRef](#)]
22. QSAR and Lead Optimization. *Computer Applications in Drug Discovery and Development*; Puratchikody, A., Prabu, S.L., Umamaheswari, A., Eds.; IGI Global: Hershey, PA, USA, 2018; Chapter 4; pp. 80–100, ISBN 9781522573265.
23. Pomarnacka, E.; Brzozowski, Z.; Filczewski, M.; Szymanska-Kosmala, M.; Oledzka, K. Various possibilities of using 6-chloro-3-methylthio-7-methyl-1,1-dioxo-1,4,2-benzodithiazine for the synthesis of 2-(4-chloro-2-mercapto-5-methylbenzenesulfonamido)imidazoline derivatives, and their pharmacological properties. *Acta Pol. Pharm.* **1985**, *42*, 501–510.
24. Pomarnacka, E.; Kornicka, A. Synthesis and in vitro anticancer and anti-HIV evaluation of new 2-mercaptobenzenesulfonamides. *Farmaco II* **2001**, *56*, 571–577. [[CrossRef](#)]
25. Liu, K.G.; Robichaud, A.J. A general and convenient synthesis of N-arylpiperazines. *Tetrahedron Lett.* **2005**, *46*, 7921–7922. [[CrossRef](#)]
26. Konstantinov, I.; Bukhryakov, K.; Gezentsvey, Y.; Krasavin, M. Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines. *Lett. Org. Chem.* **2011**, *8*, 628–630. [[CrossRef](#)]
27. Patel, R.V.; Mistry, B.; Syed, R.; Rathi, A.K.; Lee, Y.J.; Sung, J.S.; Shin, H.S.; Keum, Y.S. Chrysin piperazine conjugates as antioxidant and anticancer agents. *Eur. J. Pharm. Sci.* **2016**, *88*, 166–177. [[CrossRef](#)]
28. Kommula, D.; Polepalli, S.; Jain, N.; Murty, M.S.R. Synthesis and preliminary antiproliferative activity of novel 4-substituted phenylsulfonyl piperazines with tetrazole moiety. *Indian J. Pharm. Sci.* **2018**, *80*, 930–939. [[CrossRef](#)]
29. Guariento, S.; Tonelli, M.; Espinoza, S.; Gerasimov, A.S.; Gainetdinov, R.R.; Cichero, E. Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. *Eur. J. Med. Chem.* **2018**, *146*, 171–184. [[CrossRef](#)] [[PubMed](#)]
30. Ma, X.; Poon, T.Y.; Wong, P.T.H.; Chui, W.-K. Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5644–5647. [[CrossRef](#)]
31. Kozakiewicz, I. Syntezy niektórych pochodnych 2-[4-chloro-5-metylo-2-(2,4-diamino-1,3,5-triazyn-6-ylo)metylotiobenzenosulfonylo]iminoimidazolidyny. *Ann. Acad. Med. Gedanensis* **1998**, *28*, 155–159.
32. *The Molecular Operating Environment (MOE)*; Chemical Computing Group Inc.: Montreal, QC, Canada, 2019. Available online: <https://www.chemcomp.com/Products.htm> (accessed on 17 September 2019).
33. Monderer, D.; Shapley, L. Potential games. *Game Econ. Behav.* **1996**, *14*, 124–143. [[CrossRef](#)]
34. TIBCO Software Inc. *Statistica, Version 13*; StatSoft: Kraków, Poland, 2017.
35. Wang, S.; Zhao, Y.; Aguilar, A.; Bernard, D.; Yang, C.Y. Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: Progress and challenges. *Cold Spring Harb. Perspect. Med.* **2017**, *7*, a026245. [[CrossRef](#)]
36. Burgess, A.; Chia, K.M.; Haupt, S.; Thomas, D.; Haupt, Y.; Lim, E. Clinical overview of MDM2/X-targeted therapies. *Front. Oncol.* **2016**, *27*, 6–7. [[CrossRef](#)]
37. Moll, U.M.; Petrenko, O. The MDM2-p53 interaction. *Mol. Cancer Res.* **2003**, *1*, 1001–1008.
38. Zalcenstein, A.; Stambolsky, P.; Weisz, L.; Müller, M.; Wallach, D.; Goncharov, T.M.; Krammer, P.H.; Rotter, V.; Oren, M. Mutant p53 gain of function: Repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. *Oncogene* **2003**, *22*, 5667–5676. [[CrossRef](#)]
39. Chari, N.S.; Pinaire, N.L.; Thorpe, L.; Medeiros, L.J.; Routbort, M.J.; McDonnell, T.J. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. *Apoptosis* **2009**, *14*, 336–347. [[CrossRef](#)]
40. Hu, J.; Cao, J.; Topatana, W.; Juengpanich, S.; Li, S.; Zhang, B.; Shen, J.; Cai, L.; Cai, X.; Chen, M. Targeting mutant p53 for cancer therapy: Direct and indirect strategies. *J. Hematol. Oncol.* **2021**, *14*, 157. [[CrossRef](#)] [[PubMed](#)]
41. Lim, L.Y.; Vidnovic, N.; Ellisen, L.W.; Leong, C.O. Mutant p53 mediates survival of breast cancer cells. *Br. J. Cancer* **2009**, *101*, 1606–1612. [[CrossRef](#)] [[PubMed](#)]

42. Brzozowski, Z.; Sławiński, J. 1,1-Dioxo-1,4,2-benzodithiazine derivatives. II Synthesis of some 3-mercapto-1,1-dioxo-1,4,2-benzodithiazine derivatives. *Acta Pol. Pharm.* **1984**, *41*, 133–139.
43. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **2009**, *42*, 339–341. [[CrossRef](#)]
44. Sheldrick, G.M. SHELXT—Integrated space-group and crystalstructure determination. *Acta Cryst. A* **2015**, *71*, 3–8. [[CrossRef](#)]
45. Sheldrick, G.M. Crystal structure refinement with SHELXL. *Acta Cryst. C* **2015**, *71*, 3–8. [[CrossRef](#)]